

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Curran; et al. : Art Unit: 1652

Serial No. 10/078,927 : Examiner: David J. Steadman

Filed: February 19, 2002 : Atty Docket: SJ-01-0032

For: Cyclin Dependent Kinase 5

Phosphorylation of Disabled 1

Protein

Reply to Notice to Comply with Requirement for Patent Applications Containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, attached please find a replacement disc.

SHAWN A. HAWKINS, agent of record, hereby states as follows:

The content of the computer readable copy is the same as the paper copies included with Applicants amendment filed on April 25, 2005. The content of the computer readable copies of the Sequence Listing submitted herewith do not include new matter.

DATED: June 16, 2005

SHAWN A. HAWKINS Registration No.: 50,318

Shaun G. Howkins

PE JC TO THE STRANGER

Notice to Comply

Application No.	Applicant(s)	
10/078,927		
Examiner	Art Unit	•
STEADMAN	1652	· · · · · · · · · · · · · · · · · · ·

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking

- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: Amino acid sequences listed in claims 27-28 should be identified by a sequence identifier.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentln Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

DS